MedPath

The Study of High-protein Nutritional Support Impact on Postoperative Outcomes in Patients With Primary Lung Cancer

Completed
Conditions
Lung Cancer
Interventions
Dietary Supplement: Nutridrink Compact Protein
Registration Number
NCT05710354
Lead Sponsor
Enrollme.ru, LLC
Brief Summary

The study was aimed to evaluate the impact of perioperative nutritional support with high-protein mixtures on the risk of postoperative complications, postoperative recovery of respiratory functions in patients with lung cancer, nutritional status and quality of life of patients. Possible adverse events were also studied and described.

Detailed Description

The study enrolled 114 patients with primary non-small cell lung cancer and nutritional deficiencies or at risk of developing them, admitted for surgical treatment and meeting other inclusion/exclusion criteria. Patients were randomly divided into two groups: the study group of 57 people and the control group of 57 people.

Patients in the study group, in addition to the usual diet, received nutritional support. During the hospital stay, additional nutritional support was added to the patient's standard hospital diet. On an outpatient basis, patients received the required amount at their disposal and will take it as a supplement to his usual and habitual diet.

Patients in the control group followed the standard hospital diet, and at discharge - the usual habitual diet.

The study was conducted using Enrollme.ru electronic platform. In total, the study comprised screening and 5 visits.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
114
Inclusion Criteria
  • Presence of morphological verification of non-small cell lung cancer (NSCLC) without distant metastases;
  • Appointment of surgical treatment for primary lung cancer with anatomical resection of the lung (lobectomy, bilobectomy or pneumonectomy);
  • Nutritional deficiency or risk of its development (≥3 points on the Nutrition Risk Screening 2002 (NRS-2002) scale);
  • No history of nutritional support;
  • ECOG (Eastern Cooperative Oncology Group Performance Status Scale) score 0 - 2;
  • Life expectancy over 3 months;
  • Absence of serious diseases of the gastrointestinal tract, disorders of the liver, kidneys, systemic blood diseases and metabolic disorders at the time of inclusion in the study;
  • Absence of severe uncontrolled concomitant chronic diseases and acute diseases (including infectious ones);
  • Availability of signed informed consent for inclusion in the study and processing of personal data
Exclusion Criteria
  • Terminal state of the patient, ECOG (Eastern Cooperative Oncology Group Performance Status Scale) 3-4;
  • State of refractory cachexia;
  • Bleeding, serious injury or blood transfusions in the previous 6 months;
  • Decay / abscess in the area of the tumor lesion;
  • Presence at the same time of a tumor process of another localization, metastatic lesion of the lungs;
  • The presence of concomitant diseases in the stage of decompensation;
  • Pregnancy or lactation;
  • Allergy to or intolerance to any of the components of Nutridrink Compact Protein, galactosemia, allergy to cow's milk proteins;
  • The presence of contraindications to the use of enteral nutrition
  • Participation in another study currently or in the past 30 days;
  • Any other medical or non-medical reason that, in the physician's opinion, may prevent the patient from participating in the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
The Study GroupNutridrink Compact ProteinPatients in the study group (N=57), in addition to the usual diet, received nutritional support with the Oral Nutrition Supplement (ONS) Nutridrink Compact Protein in the amount of 2 bottles per day for 14 days prior to surgery and 14 days following surgery. During the hospital stay, additional nutritional support was added to the patient's standard hospital diet. On an outpatient basis, the patient received the required amount of ONS at his/her disposal and took it as a supplement to his/her usual and habitual diet. The ONS was recommended to be taken between main meals
Primary Outcome Measures
NameTimeMethod
Days in hospitalduring observation up to 6 weeks

Count of hospital stay after surgery

Lung complicationsduring hospital stay for about 2 weeks

Number of lung postoperative complications, e.g. lung infections, atelectasis were registered

Six Minute Walk Testduring observation up to 6 weeks

A test to count walk distance a patient can afford during 6 minutes

Hand strengthduring observation up to 6 weeks

A hand strength was measured using hand dynamometer at each visit

Weightduring observation up to 6 weeks

The weight was measured at each visit

Secondary Outcome Measures
NameTimeMethod
Serum total proteinduring observation up to 6 weeks

Serum total protein was measured at each visit

Total lymphocyte countduring observation up to 6 weeks

Serum albumin was measured at each visit

Serum albuminduring observation up to 6 weeks

Serum albumin was measured at each visit

EORTC QLQ-C30during observation up to 6 weeks

EORTC QLQ-C30 (The European Organization for Research and Treatment of Cancer core quality of life questionnaire) questionnaire was completed at visits. The questionnaire incorporates five functional scales, three symptom scales, a global health status, and a number of single items assessing additional symptoms commonly reported by cancer patients. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale and global health status represents a high / healthy level of functioning, but a high score for a symptom scale / item represents a high level of symptomatology / problems

Trial Locations

Locations (4)

Omsk Clinical Oncology health center

🇷🇺

Omsk, Russian Federation

Smolensk region Clinical Oncology health center

🇷🇺

Smolensk, Russian Federation

Mechnikov Medical University

🇷🇺

Saint Petersburg, Russian Federation

Scientific Medical center Institute of Phthisiopulmonology

🇷🇺

Saint Petersburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath